Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Flexion Therapeutics Inc. FLXN

Healthcare Drug Manufacturers - Major
Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra... see more

Recent & Breaking News (NDAQ:FLXN)

Flexion Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights

GlobeNewswire May 4, 2017

Investor Network: Flexion Therapeutics, Inc. to Host Earnings Call

Accesswire May 4, 2017

Flexion Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference

GlobeNewswire May 1, 2017

Flexion Therapeutics Highlights Two Clinical Data Presentations at the Osteoarthritis Research Society International 2017 World Congress

GlobeNewswire April 28, 2017

Flexion Therapeutics Announces Pricing of $175 Million 3.375% Convertible Senior Notes due 2024

GlobeNewswire April 26, 2017

Mid-Afternoon Market Update: iRobot Gains On Earnings Beat; Seagate Shares Plummet

Benzinga.com  April 26, 2017

Flexion Therapeutics Announces Proposed Convertible Senior Notes Offering

GlobeNewswire April 25, 2017

Flexion Therapeutics to Report First-Quarter 2017 Financial Results on May 4, 2017

GlobeNewswire April 25, 2017

How These Generic Drugs Stocks are Faring? -- Zynerba Pharma, Patheon, SCYNEXIS, and Flexion Therapeutics

PR Newswire April 11, 2017

Flexion Therapeutics Announces Appointment of Yamo Deniz, MD, as Chief Medical Officer

GlobeNewswire April 7, 2017

Flexion Therapeutics Announces Issuance of Two New Patents Further Strengthening Intellectual Property Protection (IP) for Zilretta™ (FX006)

GlobeNewswire April 4, 2017

Flexion Therapeutics to Present at Needham & Company’s 16th Annual Healthcare Conference

GlobeNewswire March 28, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  March 23, 2017

Flexion Reports Year-End 2016 Financial Results

GlobeNewswire March 9, 2017

Flexion Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire March 3, 2017

Flexion Therapeutics to Report Year-End 2016 Financial Results on March 9, 2017

GlobeNewswire March 2, 2017

Flexion Therapeutics Initiates Clinical Trial to Evaluate the Safety of Repeat Administration of Zilretta™ (FX006) in Patients with Osteoarthritis of the Knee

GlobeNewswire February 23, 2017

Flexion Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

GlobeNewswire February 15, 2017

Flexion Therapeutics Announces New Drug Application for Zilretta™ (FX006) Accepted by U.S. Food and Drug Administration

GlobeNewswire February 7, 2017

Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

GlobeNewswire December 9, 2016